Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases

Kazuma Ogawa, Hidekazu Kawashima, Kazuhiro Shiba, Kohshin Washiyama, Mitsuyoshi Yoshimoto, Yasushi Kiyono, Masashi Ueda, Hirofumi Mori, Hideo Saji

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Introduction: Based on the concept of bifunctional radiopharmaceuticals, we have previously developed 186Re-complex-conjugated bisphosphonate analogs for palliation of painful bone metastases and have demonstrated the utility of these compounds. By applying a similar concept, we hypothesized that a bone-specific directed 90Y-labeled radiopharmaceutical could be developed. Methods: In this study, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was chosen as the chelating site, and DOTA was conjugated with 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. [90Y]DOTA-complex-conjugated bisphosphonate ([90Y]DOTA-HBP) was prepared by coordination with 90Y, and its biodistribution was studied in comparison to [90Y]citrate. Results: In biodistribution experiments, [90Y]DOTA-HBP and [90Y]citrate rapidly accumulated and resided in the bone. Although [90Y]citrate showed a higher level of accumulation in the bone than [90Y]DOTA-HBP, the clearances of [90Y]DOTA-HBP from the blood and from almost all soft tissues were much faster than those of [90Y]citrate. As a result, the estimated absorbed dose ratios of soft tissues to osteogenic cells (target organ) of [90Y]DOTA-HBP were lower than those of [90Y]citrate. Conclusions: [90Y]DOTA-HBP showed superior biodistribution characteristics as a bone-seeking agent and led to a decrease in the level of unnecessary radiation compared to [90Y]citrate. Since the DOTA ligand forms a stable complex not only with 90Y but also with lutetium (177Lu), indium (111In), gallium (67/68Ga), gadolinium (Gd) and so on, complexes of DOTA-conjugated bisphosphonate with various metals could be useful as agents for palliation of metastatic bone pain, bone scintigraphy and magnetic resonance imaging.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalNuclear Medicine and Biology
Volume36
Issue number2
DOIs
Publication statusPublished - Feb 2009
Externally publishedYes

Fingerprint

Diphosphonates
Citric Acid
Neoplasm Metastasis
Bone and Bones
Radiopharmaceuticals
Lutetium
Gallium
Indium
Gadolinium
Radionuclide Imaging
Metals
Magnetic Resonance Imaging
Radiation
Ligands
Pain

Keywords

  • Bisphosphonate
  • Bone
  • DOTA
  • Palliation
  • Radiation dose
  • Yttrium-90

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Ogawa, K., Kawashima, H., Shiba, K., Washiyama, K., Yoshimoto, M., Kiyono, Y., ... Saji, H. (2009). Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nuclear Medicine and Biology, 36(2), 129-135. https://doi.org/10.1016/j.nucmedbio.2008.11.007

Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. / Ogawa, Kazuma; Kawashima, Hidekazu; Shiba, Kazuhiro; Washiyama, Kohshin; Yoshimoto, Mitsuyoshi; Kiyono, Yasushi; Ueda, Masashi; Mori, Hirofumi; Saji, Hideo.

In: Nuclear Medicine and Biology, Vol. 36, No. 2, 02.2009, p. 129-135.

Research output: Contribution to journalArticle

Ogawa, K, Kawashima, H, Shiba, K, Washiyama, K, Yoshimoto, M, Kiyono, Y, Ueda, M, Mori, H & Saji, H 2009, 'Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases', Nuclear Medicine and Biology, vol. 36, no. 2, pp. 129-135. https://doi.org/10.1016/j.nucmedbio.2008.11.007
Ogawa, Kazuma ; Kawashima, Hidekazu ; Shiba, Kazuhiro ; Washiyama, Kohshin ; Yoshimoto, Mitsuyoshi ; Kiyono, Yasushi ; Ueda, Masashi ; Mori, Hirofumi ; Saji, Hideo. / Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. In: Nuclear Medicine and Biology. 2009 ; Vol. 36, No. 2. pp. 129-135.
@article{3d10c10c0dfd4bacaa9ef2c940930dea,
title = "Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases",
abstract = "Introduction: Based on the concept of bifunctional radiopharmaceuticals, we have previously developed 186Re-complex-conjugated bisphosphonate analogs for palliation of painful bone metastases and have demonstrated the utility of these compounds. By applying a similar concept, we hypothesized that a bone-specific directed 90Y-labeled radiopharmaceutical could be developed. Methods: In this study, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was chosen as the chelating site, and DOTA was conjugated with 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. [90Y]DOTA-complex-conjugated bisphosphonate ([90Y]DOTA-HBP) was prepared by coordination with 90Y, and its biodistribution was studied in comparison to [90Y]citrate. Results: In biodistribution experiments, [90Y]DOTA-HBP and [90Y]citrate rapidly accumulated and resided in the bone. Although [90Y]citrate showed a higher level of accumulation in the bone than [90Y]DOTA-HBP, the clearances of [90Y]DOTA-HBP from the blood and from almost all soft tissues were much faster than those of [90Y]citrate. As a result, the estimated absorbed dose ratios of soft tissues to osteogenic cells (target organ) of [90Y]DOTA-HBP were lower than those of [90Y]citrate. Conclusions: [90Y]DOTA-HBP showed superior biodistribution characteristics as a bone-seeking agent and led to a decrease in the level of unnecessary radiation compared to [90Y]citrate. Since the DOTA ligand forms a stable complex not only with 90Y but also with lutetium (177Lu), indium (111In), gallium (67/68Ga), gadolinium (Gd) and so on, complexes of DOTA-conjugated bisphosphonate with various metals could be useful as agents for palliation of metastatic bone pain, bone scintigraphy and magnetic resonance imaging.",
keywords = "Bisphosphonate, Bone, DOTA, Palliation, Radiation dose, Yttrium-90",
author = "Kazuma Ogawa and Hidekazu Kawashima and Kazuhiro Shiba and Kohshin Washiyama and Mitsuyoshi Yoshimoto and Yasushi Kiyono and Masashi Ueda and Hirofumi Mori and Hideo Saji",
year = "2009",
month = "2",
doi = "10.1016/j.nucmedbio.2008.11.007",
language = "English",
volume = "36",
pages = "129--135",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases

AU - Ogawa, Kazuma

AU - Kawashima, Hidekazu

AU - Shiba, Kazuhiro

AU - Washiyama, Kohshin

AU - Yoshimoto, Mitsuyoshi

AU - Kiyono, Yasushi

AU - Ueda, Masashi

AU - Mori, Hirofumi

AU - Saji, Hideo

PY - 2009/2

Y1 - 2009/2

N2 - Introduction: Based on the concept of bifunctional radiopharmaceuticals, we have previously developed 186Re-complex-conjugated bisphosphonate analogs for palliation of painful bone metastases and have demonstrated the utility of these compounds. By applying a similar concept, we hypothesized that a bone-specific directed 90Y-labeled radiopharmaceutical could be developed. Methods: In this study, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was chosen as the chelating site, and DOTA was conjugated with 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. [90Y]DOTA-complex-conjugated bisphosphonate ([90Y]DOTA-HBP) was prepared by coordination with 90Y, and its biodistribution was studied in comparison to [90Y]citrate. Results: In biodistribution experiments, [90Y]DOTA-HBP and [90Y]citrate rapidly accumulated and resided in the bone. Although [90Y]citrate showed a higher level of accumulation in the bone than [90Y]DOTA-HBP, the clearances of [90Y]DOTA-HBP from the blood and from almost all soft tissues were much faster than those of [90Y]citrate. As a result, the estimated absorbed dose ratios of soft tissues to osteogenic cells (target organ) of [90Y]DOTA-HBP were lower than those of [90Y]citrate. Conclusions: [90Y]DOTA-HBP showed superior biodistribution characteristics as a bone-seeking agent and led to a decrease in the level of unnecessary radiation compared to [90Y]citrate. Since the DOTA ligand forms a stable complex not only with 90Y but also with lutetium (177Lu), indium (111In), gallium (67/68Ga), gadolinium (Gd) and so on, complexes of DOTA-conjugated bisphosphonate with various metals could be useful as agents for palliation of metastatic bone pain, bone scintigraphy and magnetic resonance imaging.

AB - Introduction: Based on the concept of bifunctional radiopharmaceuticals, we have previously developed 186Re-complex-conjugated bisphosphonate analogs for palliation of painful bone metastases and have demonstrated the utility of these compounds. By applying a similar concept, we hypothesized that a bone-specific directed 90Y-labeled radiopharmaceutical could be developed. Methods: In this study, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was chosen as the chelating site, and DOTA was conjugated with 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. [90Y]DOTA-complex-conjugated bisphosphonate ([90Y]DOTA-HBP) was prepared by coordination with 90Y, and its biodistribution was studied in comparison to [90Y]citrate. Results: In biodistribution experiments, [90Y]DOTA-HBP and [90Y]citrate rapidly accumulated and resided in the bone. Although [90Y]citrate showed a higher level of accumulation in the bone than [90Y]DOTA-HBP, the clearances of [90Y]DOTA-HBP from the blood and from almost all soft tissues were much faster than those of [90Y]citrate. As a result, the estimated absorbed dose ratios of soft tissues to osteogenic cells (target organ) of [90Y]DOTA-HBP were lower than those of [90Y]citrate. Conclusions: [90Y]DOTA-HBP showed superior biodistribution characteristics as a bone-seeking agent and led to a decrease in the level of unnecessary radiation compared to [90Y]citrate. Since the DOTA ligand forms a stable complex not only with 90Y but also with lutetium (177Lu), indium (111In), gallium (67/68Ga), gadolinium (Gd) and so on, complexes of DOTA-conjugated bisphosphonate with various metals could be useful as agents for palliation of metastatic bone pain, bone scintigraphy and magnetic resonance imaging.

KW - Bisphosphonate

KW - Bone

KW - DOTA

KW - Palliation

KW - Radiation dose

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=59649125010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649125010&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2008.11.007

DO - 10.1016/j.nucmedbio.2008.11.007

M3 - Article

C2 - 19217524

AN - SCOPUS:59649125010

VL - 36

SP - 129

EP - 135

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 2

ER -